All Multiple Sclerosis articles
-
PodcastInterferon beta
An immune-modulating compound used to reduce the symptoms of multiple sclerosis and now showing potential against coronaviruses
-
BusinessUS government urged to exercise drug patent rights
Campaign group says withdrawing Biogen’s license to government patents, or re-licensing them to other companies, could lower MS drug prices
-
BusinessBiogen pays $1.25bn to protect multiple sclerosis drug sales
Agreement with Forward Pharma gives Biogen license to keep selling blockbuster Tecfidera
-
Business
Novartis to buy experimental MS drug from GSK in $1bn deal
Deal will help to bolster Novartis’s pipeline for neurological disorder treatments
-
Business
Talk of a $6.6bn deal for Elan
Potential offer from Royalty Pharma comes as Elan ponders how to spend its cash from Tysabri rights
-
Business
Biogen buys Tysabri from Elan for $3.25bn
Elan earns huge cash injection for blockbuster drug